Biofrontera strengthens commercial focus with reorganization of its US business
06 janv. 2020 09h00 HE
|
Biofrontera AG
Leverkusen, Germany, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced a new...
Extraordinary General Meeting of Biofrontera AG: Biofrontera Management Board supported by large majority
20 déc. 2019 09h35 HE
|
Biofrontera AG
Leverkusen, Germany, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced the...
Christopher Pearson appointed new Chief Commercial Officer at US subsidiary Biofrontera Inc.
13 déc. 2019 08h20 HE
|
Biofrontera AG
Leverkusen, Germany, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced today that...
Biofrontera to Participate in Upcoming Investor Conferences
22 nov. 2019 11h06 HE
|
Biofrontera AG
Leverkusen, Germany, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced its...
Biofrontera Reports Third Quarter 2019 Financial Results and Revises Guidance
19 nov. 2019 03h25 HE
|
Biofrontera AG
Leverkusen, Germany, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced its...
Biofrontera Announces Conference Call on November 19, 2019 to Discuss Third Quarter 2019 Financial Results
06 nov. 2019 05h30 HE
|
Biofrontera AG
Leverkusen, Germany, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Biofrontera Receives Award at Fall Clinical Dermatology Conference 2019
23 oct. 2019 02h00 HE
|
Biofrontera AG
Leverkusen, Germany, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, was presented with...
Biofrontera reports preliminary unaudited sales revenue for the first nine months of 2019
10 oct. 2019 05h15 HE
|
Biofrontera AG
Leverkusen, Germany, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-group”), an international biopharmaceutical...
Biofrontera to present at the Baader Investment Conference
17 sept. 2019 09h45 HE
|
Biofrontera AG
Leverkusen, Germany, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced that Prof....
Biofrontera Files Label Extension for Ameluz® in EU to include Treatment of Actinic Keratosis on Extremities and Trunk/Neck
17 sept. 2019 05h45 HE
|
Biofrontera AG
Leverkusen, Germany, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, has filed a label...